GeneHealth - Your precision medicine

Insulinoma

Disease Details

Family Health Simplified

Buy Membership

Description: Insulinoma is a rare pancreatic tumor that secretes excessive insulin, leading to hypoglycemia.
Type: Insulinoma is typically a type of pancreatic neuroendocrine tumor. It is usually sporadic, meaning it occurs randomly rather than being inherited. In rare cases, it can be associated with genetic conditions like Multiple Endocrine Neoplasia type 1 (MEN1), which is inherited in an autosomal dominant pattern.
Signs And Symptoms: Patients with insulinomas usually develop neuroglycopenic symptoms. These include recurrent headache, lethargy, diplopia, and blurred vision, particularly with exercise or fasting. Severe hypoglycemia may result in seizures, coma, and permanent neurological damage. Symptoms resulting from the catecholaminergic response to hypoglycemia (i.e. tremulousness, palpitations, tachycardia, sweating, hunger, anxiety, nausea) are not as common. Sudden weight gain is sometimes seen.
Prognosis: Most patients with benign insulinomas can be cured with surgery. Persistent or recurrent hypoglycemia after surgery tends to occur in patients with multiple tumours. About 2% of patients develop diabetes mellitus after their surgery.
Onset: Insulinoma is a rare tumor of the pancreas that results in the overproduction of insulin. The onset typically occurs between the ages of 40 and 60, though it can also occur in younger individuals.
Prevalence: Insulinoma is a rare type of pancreatic tumor. Its prevalence is approximately 1 to 4 cases per million people per year.
Epidemiology: Epidemiology: Insulinoma is a rare type of neuroendocrine tumor originating from the insulin-producing beta cells of the pancreas. The incidence is approximately 1 to 4 cases per million people per year. It commonly occurs in adults, with a peak incidence between the ages of 40 and 60, and is slightly more prevalent in women than in men. Most insulinomas are benign, with about 90% being non-malignant.
Intractability: Insulinoma is generally not considered an intractable disease. It is a type of pancreatic neuroendocrine tumor that produces excessive insulin. Most insulinomas are benign and can be effectively treated with surgical removal. In cases where surgery is not possible or for malignant insulinomas, other treatments such as medication to manage symptoms or targeted therapies can be employed. However, each patient's situation is unique, and management strategies should be tailored to individual needs.
Disease Severity: Insulinoma is a rare, typically benign tumor of the insulin-producing beta cells in the pancreas. While most insulinomas are benign, they can still cause serious health issues due to excess insulin production, leading to severe hypoglycemia (low blood sugar levels). The severity can vary:

1. **Symptoms and Complications:** Symptoms may include confusion, sweating, weakness, and seizures due to hypoglycemia. Severe or prolonged hypoglycemia can result in neurological damage or death.
2. **Treatment:** With appropriate treatment, including surgical removal of the tumor and management of blood sugar levels, the prognosis is generally good.
3. **Potential for Malignancy:** In rare cases, insulinomas can be malignant and metastasize, which would significantly worsen the prognosis.

Overall, while benign insulinomas are often manageable and have a good outcome with treatment, the severity can be high if not properly diagnosed and treated due to the risk of life-threatening hypoglycemia.
Healthcare Professionals: Disease Ontology ID - DOID:3892
Pathophysiology: Pathophysiology of insulinoma involves the autonomous secretion of insulin by beta cells of the pancreatic islets. This excessive and uncontrolled insulin release leads to hypoglycemia, which persists regardless of dietary intake. Typically, the underlying mechanism includes a benign tumor originating from these beta cells, although malignant forms are rare. Elevated insulin levels suppress hepatic glucose production and enhance peripheral glucose uptake, exacerbating hypoglycemia and resulting in symptoms such as confusion, weakness, and in severe cases, loss of consciousness.
Carrier Status: Insulinoma is a rare, typically benign tumor of the pancreas that produces excessive amounts of insulin. It is generally not inherited, and there are no carriers of this condition in the genetic sense. It most commonly occurs sporadically without a known cause or hereditary pattern.
Mechanism: Insulinoma is a rare, typically benign tumor of the pancreas that arises from the beta cells, which are responsible for insulin production.

Mechanism:
- These tumors secrete excessive amounts of insulin, independent of blood glucose levels. This leads to recurrent episodes of hypoglycemia (low blood sugar). The excessive insulin secretion occurs even when glucose levels are already low, which would normally suppress insulin release in healthy individuals.

Molecular Mechanisms:
- Genetic Mutations: Insulinomas are often associated with mutations in the MEN1 gene, which codes for menin, a tumor suppressor protein. Loss of function of menin can lead to uncontrolled cellular proliferation.
- Pathways: Dysregulation of the mammalian target of rapamycin (mTOR) pathway and the AKT/PKB signaling pathway has been implicated in insulinoma development. These pathways are involved in cell growth, proliferation, and survival.
- Chromosomal Instabilities: Some insulinomas may show chromosomal abnormalities, including losses and gains in specific chromosomal regions, contributing to tumorigenesis.

Detection of these molecular alterations can aid in the diagnosis and potentially in the development of targeted therapies.
Treatment: The definitive management is the surgical removal of the insulinoma. This may involve removing part of the pancreas, as well (Whipple procedure and distal pancreatectomy).
Medications such as diazoxide and somatostatin can be used to block the release of insulin for patients who are not surgical candidates or who otherwise have inoperable tumours.
Streptozotocin is used in islet cell carcinomas which produce excessive insulin. Combination chemotherapy is used, either doxorubicin and streptozotocin, or fluorouracil and streptozocin in patients where doxorubicin is contraindicated.
In metastasizing tumours with intrahepatic growth, hepatic arterial occlusion or embolization can be used.
Compassionate Use Treatment: For insulinoma:

**Compassionate Use Treatment:**
1. **Everolimus**: An mTOR inhibitor used under compassionate use for patients with advanced insulinomas when standard therapies are ineffective.
2. **Sunitinib**: A tyrosine kinase inhibitor that may be offered on a compassionate basis for managing advanced or metastatic insulinomas.

**Off-label or Experimental Treatments:**
1. **Diazoxide**: Though primarily used for hypertensive crises, it is often administered off-label to inhibit insulin release and manage hypoglycemia in insulinoma patients.
2. **Octreotide**: A somatostatin analog which may be used off-label to control symptoms of insulinoma by inhibiting insulin and other hormone secretions.
3. **Peptide Receptor Radionuclide Therapy (PRRT)**: This experimental treatment involves using radioactive substances that bind to somatostatin receptors on tumor cells, such as lutetium-177 DOTATATE, to deliver targeted radiation therapy.
4. **Targeted Therapies**: Other targeted therapies, such as everolimus (beyond its compassionate use), are being explored experimentally for their efficacy in treating insulinomas.
5. **Chemotherapy Regimens**: Various chemotherapeutic agents, though not standard, are being investigated in experimental settings to treat malignant or advanced insulinomas.

These treatments are typically considered when conventional therapeutic options have been exhausted or are not suitable for the patient.
Lifestyle Recommendations: Lifestyle recommendations for managing insulinoma:

1. **Diet Modifications:**
- Eat small, frequent meals throughout the day to maintain stable blood sugar levels.
- Focus on a balanced diet with a good mix of proteins, healthy fats, and complex carbohydrates.
- Avoid high-sugar snacks and beverages that can cause rapid spikes and drops in blood glucose.

2. **Monitor Blood Sugar:**
- Regularly monitor blood glucose levels to detect and manage hypoglycemia early.
- Keep glucose tablets or other quick sources of sugar on hand to treat low blood sugar episodes promptly.

3. **Physical Activity:**
- Engage in regular, moderate exercise, but be cautious as physical activity can affect blood sugar levels.
- Monitor glucose levels before, during, and after exercise, and adjust intake accordingly.

4. **Medical Management:**
- Follow the treatment plan prescribed by your healthcare provider, which may include medications or surgery.
- Schedule regular follow-up appointments to monitor your condition and adjust treatment as necessary.

5. **Stress Management:**
- Practice stress-reduction techniques such as mindfulness, yoga, or deep-breathing exercises, as stress can affect blood sugar levels.

6. **Education and Awareness:**
- Educate yourself about the signs and symptoms of hypoglycemia and how to manage them.
- Inform family, friends, and coworkers about your condition and how they can help in case of emergencies.

Consult with your healthcare provider for personalized advice.
Medication: Insulinoma is a rare pancreatic tumor that produces excess insulin. Medication treatment may include diazoxide to inhibit insulin release and octreotide to suppress insulin production. Consult a healthcare professional for appropriate management.
Repurposable Drugs: Insulinoma is a rare pancreatic tumor that results in excessive insulin production. Some repurposable drugs that have been explored for insulinoma include:

1. **Diazoxide**: This drug inhibits insulin release from the pancreas and is often used to manage symptoms of hyperinsulinemia caused by insulinoma.
2. **Octreotide**: A somatostatin analog that can suppress insulin secretion temporarily and has been used to control symptoms.
3. **Everolimus**: An mTOR inhibitor that has shown some efficacy in controlling tumor growth and insulin secretion in neuroendocrine tumors, including insulinomas.
4. **Verapamil**: A calcium channel blocker that has been studied for its potential to modulate insulin secretion in insulinoma cases.

These are not definitive treatments, and the management of insulinoma typically involves a combination of medical therapy and surgical intervention depending on the specific case.
Metabolites: Insulinoma is a type of pancreatic islet cell tumor that secretes excessive insulin. Key metabolites associated with insulinoma include:

1. **Insulin:** Elevated levels due to tumor secretion.
2. **C-peptide:** Typically elevated, helps distinguish endogenous insulin production from exogenous sources.
3. **Proinsulin:** Often elevated, as insulinomas may secrete this precursor hormone.
4. **Glucose:** Frequently low (hypoglycemia) due to excessive insulin secretion.

Nan (not a number) values are generally not related to insulinoma. If "nan" refers to specific advanced technologies or techniques involving nanoparticles, such specificity is not inherently linked to standard diagnosis or treatment protocols for insulinoma.
Nutraceuticals: Insulinoma is a rare pancreatic tumor that secretes excessive amounts of insulin, leading to hypoglycemia. There is currently no specific nutraceutical therapy for insulinoma. Treatment typically involves surgical removal of the tumor. Some nutraceuticals can potentially help manage blood sugar levels, but they are not a substitute for conventional treatments. Always consult a healthcare provider before starting any supplement regime for insulinoma.
Peptides: Insulinoma is a rare, typically benign tumor of the pancreas that secretes insulin. It arises from the beta cells of the islets of Langerhans. The primary peptide involved is insulin, which is inappropriately secreted in excess. This leads to hypoglycemia, because insulin lowers blood glucose levels.

NAN (number of cases annually) for insulinoma is difficult to pinpoint exactly, but it is estimated to occur in approximately 1-4 people per million per year.